Functional Profiling Demonstrates That a Sulfide-Reducing Diet Achieves Microenvironmental Targets in Ulcerative Colitis
- PMID: 40900671
- PMCID: PMC12638066
- DOI: 10.1093/ibd/izaf177
Functional Profiling Demonstrates That a Sulfide-Reducing Diet Achieves Microenvironmental Targets in Ulcerative Colitis
Abstract
Background: As a dietary approach to reducing inflammation in ulcerative colitis, the 4-SURE (4 Strategies to Sulfide Reduction) diet was designed to correct pathogenic alterations of excessive protein fermentation and hydrogen sulfide (H2S) production in the distal colon. We aimed to perform a deep functional analysis (microbial and metabolomic) of the feces of 28 adults with mild-moderately active ulcerative colitis who adhered to the 4-SURE diet over 8 weeks to explore whether the 4-SURE diet could modulate the intraluminal environment as intended.
Methods: Fecal samples were collected at week 0 and 8 of dietary intervention, processed and aliquoted. Metagenomic sequencing was undertaken to identify changes in H2S-metabolizing genes, while gas chromatography-mass spectrometry was used to analyze fecal volatile organic compounds and H2S production.
Results: The 4-SURE diet significantly increased alpha diversity between weeks 0 and 8. By random forest plot classifier, the abundance of taxonomic groups comprising known H2S-producing genera were markedly lower at week 8, specifically Odoribacter and Peptostreptococcaceae, and were of highest importance in discriminating between before- and after-diet samples. The capacity for bacterial H2S metabolism was altered with diet, with differences in 12 of 67 analyzed sulfur-metabolizing genes identified. H2S production and indole, a specific marker of protein fermentation, were significantly decreased due to the diet.
Conclusions: Here, we demonstrate that the objectives of the 4-SURE diet were fulfilled. This application of deep functional analysis to a dietary intervention study is novel and highlights an exemplar framework for including microbial and metabolomic biomarkers of pathogenic relevance in the analysis of therapeutic diet strategies. (Australian New Zealand Clinical Trials Registry, Number: ACTRN12619000063112).
Plain language summary
The 4-SURE diet reduced protein fermentation and microbial hydrogen sulfide production in adults with ulcerative colitis, demonstrating its intended intraluminal effects. This study proposes a successful framework for evaluating therapeutic diets using integrated microbial and metabolomic analysis.
© The Author(s) 2025. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Conflict of interest statement
ASD has no competing interests to declare. RS reports there are no competing interests to declare. RZW is an option holder in BiomeBank. RBY is an option holder in BiomeBank. WU has no competing interests to declare. NKM has no competing interests to declare. VRM reports there are no competing interests to declare. SCF owns shares in BiomeBank SPC owns shares in BiomeBank. SPC has received advisory, speaking fees or research support from Ferring, Falk, Microbiotica, Janssen. CJP has no competing interests to declare. JMA has served as a speaker, a consultant and an advisory board member for, and has received research funding from, Abbott, AbbVie, Allergan, Anatara, AstraZeneca, Bayer, Celgene, Falk, Ferring, Gilead, Hospira, Immunic, ImmunsanT, Janssen, MSD, Nestle, Progenity, Pfizer, Sandoz, Shire, Takeda, Vifor, RAH Research Fund, The Hospital Research Fund with all monies received by her department for research support. CKY has received research funding from Atmo Biosciences, Ferring Pharmaceuticals, Danone and Yakult Australia. Her Department financially benefits from the sales of a digital application, booklets and on-line courses on the FODMAP diet. PRG has served as a consultant or advisory board member for Anatara, Atmo Biosciences, Immunic Therapeutics, Novoviah, Novozymes, Intrinsic Medicine, Topas and Comvita. He has received research grants for investigator-driven studies from Atmo Biosciences. He holds shares in Atmo Biosciences. His department financially benefits from the sales of a digital application, booklets and online courses on the FODMAP diet RVB has served as a speaker, a consultant and an advisory board member for (all fees paid to employer for research support), and has received research funding from AbbVie, Ferring, Janssen, Shire, Takeda, Dr Falk, Emerge Health. RVB owns shares in BiomeBank.
Figures
Comment in
-
Deciphering Mechanisms Underlying Success of Microbiome-Targeted Diet Therapy in Ulcerative Colitis.Inflamm Bowel Dis. 2025 Sep 23:izaf203. doi: 10.1093/ibd/izaf203. Online ahead of print. Inflamm Bowel Dis. 2025. PMID: 40985460 No abstract available.
References
-
- Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205-217. - PubMed
-
- Lambert K, Pappas D, Miglioretto C, et al. Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2021;54:742-754. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
